Ideas

Cardiovascular Polypill-LAAH attenuates pathogenesis-associated with Myocardial infarction and protects against myocardial dysfunction:   A four-component Polypill-LAAH consisting of Losartan(25 mg), Amlodipine (2.5 mg), Atorvastatin (10 mg), and Hydrochlorothiazide (12·5 mg)decreases IRF3, GM-CSF (Granulocyte-macrophage colony-stimulating factor) and GRK2(G protein-coupled receptor kinase) expression, inhibits undue leukocyte activation and invasion, suppresses recruitment of inflammatory cells, inhibits ventricular dilation, and promotes heart repair and survival, via up regulation of its target genes, 1/October/2019, 12.04 pm
Cardiovascular Polypill-LAAH attenuates pathogenesis-associated with Myocardial infarction and protects against myocardial dysfunction:   A four-component Polypill-LAAH consisting of Losartan(25 mg), Amlodipine (2.5 mg), Atorvastatin (10 mg), and Hydrochlorothiazide (12·5 mg)decreases IRF3, GM-CSF (Granulocyte-macrophage colony-stimulating factor) and GRK2(G protein-coupled receptor kinase) expression, inhibits undue leukocyte activation and invasion, suppresses recruitment of inflammatory cells, inhibits ventricular dilation, and promotes heart repair and survival, via up regulation of its target genes, 1/October/2019, 12.04 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say:  A recent study from Department of Systems Biology, Harvard Medical School, Boston, Massachusetts, USA; and Cardiovascular Research Center, Massachusetts General Hospital and Harvard Medical School, Boston,…

read more

Molecular mechanistic insight into how Dapagliflozin (DAPA)  protects against and promotes functional recovery after Myocardial Infarction:  Dapagliflozin (DAPA) (trade name: Forxiga, Farxiga, others), a medication used to treat type II diabetes,  inhibits DNA damage responses, induces telomerase expression, inhibits telomere shortening, and promotes cardiomyocyte survival after myocardial infarction, via up-regulation of its target gene, 26/September/2019, 3.58 pm
Molecular mechanistic insight into how Dapagliflozin (DAPA)  protects against and promotes functional recovery after Myocardial Infarction:  Dapagliflozin (DAPA) (trade name: Forxiga, Farxiga, others), a medication used to treat type II diabetes,  inhibits DNA damage responses, induces telomerase expression, inhibits telomere shortening, and promotes cardiomyocyte survival after myocardial infarction, via up-regulation of its target gene, 26/September/2019, 3.58 pm 1280 720 Dr Boomi's Genom-2-Discovery Center

What they say:  A recent study from the Institute for Cardiovascular Regeneration, Centre of Molecular Medicine, Frankfurt, Germany shows that “MicroRNA-34a regulates cardiac ageing and function.” This study was published, in the 7 March  2013 issue of of the journal Nature,  by Prof Dimmler…

read more

Polypill for Cardioprotection: Polypill-HAAE/HAAV-based therapy for Cardiac repair and myocardial infarction: A four-component  Polypill-HAAE/HAAV consisting of Hydrochlorothiazide (12·5 mg), Aspirin (81 mg), Atorvastatin (20 mg), and Enalapril (5 mg)  or Valsartan (40 mg)  increases Agrin expression, activates Yap and ERK-mediated signaling,  replaces scar tissue with functional cardiomyocytes, and promotes cardiomyocyte regeneration and repair after myocardial infarction, via up-regulation of its target gene, 25/September/2019,  8.45 pm
Polypill for Cardioprotection: Polypill-HAAE/HAAV-based therapy for Cardiac repair and myocardial infarction: A four-component  Polypill-HAAE/HAAV consisting of Hydrochlorothiazide (12·5 mg), Aspirin (81 mg), Atorvastatin (20 mg), and Enalapril (5 mg)  or Valsartan (40 mg)  increases Agrin expression, activates Yap and ERK-mediated signaling,  replaces scar tissue with functional cardiomyocytes, and promotes cardiomyocyte regeneration and repair after myocardial infarction, via up-regulation of its target gene, 25/September/2019,  8.45 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say: A recent study from Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot 76100, Israel; Department of Biomedical Engineering, Duke University, Durham, North Carolina 27708,…

read more

Solving a sixty plus year of puzzle as to how Dexamethasone functions as a pain reliever: Mechanistic insights into how Dexamethasone functions as an analgesic agent: Dexamethasone (trade name: Boycadron, Decadron, Dexasone, Diodex, hexadrol, maxidex and others), used to treat moderate to severe pain during labor and delivery, in post-operative pain management, in chronic cancer pain management and in others,  increases the expression of PD-L1, decreases the expression of Cox-2, TRPV1, and CGPR, attenuates acutes and chronic pain, and suppresses mechanical and thermal hypersensitivity and inhibits nociceptive neuron excitability, via up-regulation of its target gene, 24/September/2019, 11.45 am
Solving a sixty plus year of puzzle as to how Dexamethasone functions as a pain reliever: Mechanistic insights into how Dexamethasone functions as an analgesic agent: Dexamethasone (trade name: Boycadron, Decadron, Dexasone, Diodex, hexadrol, maxidex and others), used to treat moderate to severe pain during labor and delivery, in post-operative pain management, in chronic cancer pain management and in others,  increases the expression of PD-L1, decreases the expression of Cox-2, TRPV1, and CGPR, attenuates acutes and chronic pain, and suppresses mechanical and thermal hypersensitivity and inhibits nociceptive neuron excitability, via up-regulation of its target gene, 24/September/2019, 11.45 am 1280 720 Dr Boomi's Genom-2-Discovery Center

Introduction:What they say: A recent study from Institute of Neurobiology, Institutes of Brain Science and State Key Laboratory of Medical Neurobiology, Collaborative Innovation Center for Brain Science, Fudan University, Shanghai,…

read more

Senolytics therapy for cardiac repair, cardiac regeneration and cardioprotection: Combinatorial therapy for postnatal Cardiomyocyte proliferation, repair and regeneration:  A two-component Pill consisting of Dasatinib and Quercetin (Pill-DQ) decreases tumor suppressor MiR-128 and cyclin-dependent kinase inhibitor p27 expression, increases SUZ12 expression, increases Cyclin E and CDK2 expression, promotes proliferation/re-entry of postnatal/adult cardiomyocytes, attenuates fibrosis, ameliorates cardiac dysfunction, and promotes heart repair in response to myocardial infarction, via up-regulation of its target gene, 20/September/2019, 7.39 am
Senolytics therapy for cardiac repair, cardiac regeneration and cardioprotection: Combinatorial therapy for postnatal Cardiomyocyte proliferation, repair and regeneration:  A two-component Pill consisting of Dasatinib and Quercetin (Pill-DQ) decreases tumor suppressor MiR-128 and cyclin-dependent kinase inhibitor p27 expression, increases SUZ12 expression, increases Cyclin E and CDK2 expression, promotes proliferation/re-entry of postnatal/adult cardiomyocytes, attenuates fibrosis, ameliorates cardiac dysfunction, and promotes heart repair in response to myocardial infarction, via up-regulation of its target gene, 20/September/2019, 7.39 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say: A recent study from Department of Pathology and Laboratory Medicine, University of Cincinnati College of Medicine, Cincinnati, OH, 45267, USA; Key Laboratory of Molecular Target and…

read more

Probiotic-based Chemotherapy (PCT) targeting cancer stem cells and immune-inhibitory receptors in metastatic breast cancer and in other advanced metastatic cancers: A pharmaceutical mixture encompassing Palbociclib,  Fulvestrant and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as TPM1 and CADM1/2,  p53, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets cancer stem cells, confers protection against chemoresistance and prolongs survival, and stalls metastatic breast cancer  progression, via up-regulation of its target gene, 19/September/2019, 10.29 pm
Probiotic-based Chemotherapy (PCT) targeting cancer stem cells and immune-inhibitory receptors in metastatic breast cancer and in other advanced metastatic cancers: A pharmaceutical mixture encompassing Palbociclib,  Fulvestrant and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as TPM1 and CADM1/2,  p53, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets cancer stem cells, confers protection against chemoresistance and prolongs survival, and stalls metastatic breast cancer  progression, via up-regulation of its target gene, 19/September/2019, 10.29 pm 1280 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from Institute of Cancer Research and Royal Marsden Hospital, London, David Geffen School of Medicine at University of California, Los Angeles, Santa Monica, and Pfizer Oncology,…

read more
Start Typing